Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Pajtler, KW; Tippelt, S; Siegler, N; Reichling, S; Zimmermann, M; Mikasch, R; Bode, U; Gnekow, A; Pietsch, T; Benesch, M; Rutkowski, S; Fleischhack, G.
Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors.
J Neurooncol. 2016; 128(3):463-471
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Benesch Martin
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Systemic administration of etoposide is effective in treating metastatic, recurrent or refractory brain tumors, but penetration into the cerebrospinal fluid is extremely poor. This study was designed to determine the safety and toxicity profile of intraventricular etoposide administration and was affiliated with the prospective, multicenter, nonblinded, nonrandomized, multi-armed HIT-REZ-97 trial. The study enrolled 68 patients, aged 1.1-34.6 (median age 11 years). Adverse events that could possibly be related to intraventricular etoposide therapy were documented and analyzed. Intraventricular etoposide was simultaneously administered with either oral or intravenous chemotherapy in 426 courses according to three major schedules varying in dosing (0.25-1 mg), frequency of administration (bolus injection, every 12 or 24 h), course duration (5-10 days) and length of interval between courses (2-5 weeks). Potential treatment-related adverse effects included transient headache, seizures, infection of the reservoir, nausea and neuropsychological symptoms. Hematological side effects were not observed. One patient, with history of multiple prior therapies, who received long-term intraventricular and oral etoposide treatment developed acute myeloid leukemia as a secondary malignancy. Overall intraventricular etoposide is well tolerated. The results of this study have warranted a phase II trial to determine the effectiveness of this regimen in disease stages with very limited therapeutic options.
Find related publications in this database (using NLM MeSH Indexing)
Adolescent -
Adult -
Antineoplastic Agents, Phytogenic - administration & dosage
Antineoplastic Agents, Phytogenic - adverse effects
Brain Neoplasms - drug therapy
Cerebral Ventricles -
Child -
Child, Preschool -
Drug Therapy, Combination -
Etoposide - administration & dosage
Etoposide - adverse effects
Female -
Follow-Up Studies -
Humans -
Infant -
Male -
Treatment Outcome -
Young Adult -

Find related publications in this database (Keywords)
Ependymoma
Medulloblastoma
ATRT
Relapse
Progression
Pediatric brain tumors
© Meduni Graz Impressum